CoChat

Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease

Open access
Charles, David, Konrad, Peter E., Neimat, Joseph S., Molinari, Anna L., Tramontana, Michael G., Finder, Stuart G., Gill, Chandler E., Bliton, Mark J., Kao, Chris, Phibbs, Fenna T., Hedera, Peter, Salomon, Ronald M., Cannard, Kevin R., Wang, Lily, Song, Yanna, Davis, Thomas L. · 2014 · Parkinsonism & Related Disorders
Cited by 132

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson’s disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. Methods Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50–75, on medication ≥ 6 months but < 4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n=15) or DBS+ODT (n=15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. Results As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. The DBS+ODT group took less medication at all time points, and this reached maximum difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS+ODT group suffered serious adverse events; remaining adverse events were mild or transient. Conclusions This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.parkreldis.2014.03.019

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 132

Metadata

Authors
Charles, D., Konrad, P. E., Neimat, J. S., Molinari, A. L., Tramontana, M. G., Finder, S. G., Gill, C. E., Bliton, M. J., Kao, C., Phibbs, F. T., Hedera, P., Salomon, R. M., Cannard, K. R., Wang, L., Song, Y., & Davis, T. L.
Venue
Parkinsonism & Related Disorders
Publisher
Elsevier BV
Published
2014-07
Volume
20
Issue
7
Pages
731-737
ISSN
1353-8020 (ISSN-L)
OpenAlex
W2056089860
Cited by
132
References
2
FWCI
10.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. https://app.cochat.ai/papers/10.1016/j.parkreldis.2014.03.019
The paper
Charles, D., Konrad, P. E., Neimat, J. S., Molinari, A. L., Tramontana, M. G., Finder, S. G., Gill, C. E., Bliton, M. J., Kao, C., Phibbs, F. T., Hedera, P., Salomon, R. M., Cannard, K. R., Wang, L., Song, Y., & Davis, T. L. (2014). Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. Parkinsonism & Related Disorders. https://doi.org/10.1016/j.parkreldis.2014.03.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.